Paradromics

Brain-Computer Interfaces·Private

Tech Score60AdvancingOPINION

Goal milestone FDA-approved commercial brain-computer interface

High-bandwidth Connexus BCI; first human recording in 2025 (20-minute procedure). Funded via a NEOM-led round.

Founded2015 HQAustin, TX, US Websitewww.paradromics.com ↗

Technology ↔ market gap

Verified technical progress over time. Market valuation overlays once delayed data connects.

Technical progress Market valuation

Trajectory builds as milestones accumulate.

Verified stage

2.0 / 5

Market-impliedAwaiting market data

GapOPINIONAwaiting market data

Catalysts

Stock-moving events from the newsroom feed — facts, not advice. No rating, no price target.

2026-09-15

Credibility

A Connexus implant let a woman speak her own words — and told attempted speech from imagined

source · Paradromics / Business Wire ↗ read ↗

2026-07-06

Commercialization

Paradromics' wireless BCI gets its first-in-human implant at the University of Michigan

source · Michigan Medicine ↗ read ↗

Technical milestones

Verified progress on the Frontier Milestones tracker ↗

From the verified Frontier Milestones dataset.

2025-05

Stage 2

Third company implants a human BCI

source ↗

2026-08

Stage 2

FDA clears an implanted BCI to drive everyday personal devices

source ↗

2026-09-14

Stage 2

Unscripted real-time speech from a high-channel implant

source ↗

Distance to goal 40%

FDA-approved commercial brain-computer interface

Market data

Cumulative funding$108M

Quantitative factors

Computed once market data connects (price, market cap, runway).

Commentary

No analyst commentary published yet.

Commentary reflects one analyst’s view and is not a recommendation. It is presented alongside factual data and is explicitly labelled opinion.

Discussion0

Member discussion. Not investment advice, solicitation, or a recommendation.

Loading…

LICENSE-GATED Ratings & price targets are not shown. FM Invest does not display buy / hold / sell ratings or price targets until investment-advisory licensing is in place. The schema exists and is gated to zero exposure until then.

For information only. Not investment advice and not a solicitation. Market data is delayed and provided “as is”; technical data is read from the Frontier Milestones verified dataset.